MGC Pharma has signed a worldwide agreement with European nutraceuticals company Swiss PharmaCan for distribution of its ArtemiC Rescue product as a food supplement.
The deal follows the successful completion of a phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients to evaluate the safety and efficacy of ArtemiC Rescue as a treatment in December 2020.
The three-year agreement provides MGC Pharma with direct access to large and growing markets that are still reporting high numbers of COVID-19 cases.
MGC Pharma co-founder and managing director Roby Zomer said: “Following the successful results achieved from our phase two clinical trial in December, we are very pleased to have signed this agreement with Swiss PharmaCan for worldwide distribution of our anti-inflammatory product as a food supplement as it provides full product validation of its therapeutic benefits.”